Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U1VZ
|
|||
| Former ID |
DIB012841
|
|||
| Drug Name |
Flurpiridaz F 18
|
|||
| Synonyms |
Flurpiridaz (18F); PET myocardial perfusion imaging agents, Bristol-Myers Squibb Medical Imaging; RP-1003-18; RP-1004-18; RP-1005-18; [18F]-RP-1003; [18F]-RP-1004; [18F]-RP-1005; [18F]-labeled PET myocardial perfusion imaging agents, Lantheus Medical Imaging; BMS-747158-02-[18F]; Fluorine-18-BMS-747158; [18F]-labeled MC-1 inhibitors (MPIAs), Lantheus Medical Imaging; [18F]-labeled MC-1 inhibitors, Bristol-Myers Squibb Medical Imaging; [18fluorine]-labeled mitochondrial complex-1 inhibitors, Bristol-Myers Squibb Medical Imaging; 18F-BMS-747158-02
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myocardial disease [ICD-11: BC43.20; ICD-10: I42.3, I42.4] | Phase 3 | [1] | |
| Company |
Lantheus medical imaging
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22ClFN2O3
|
|||
| Canonical SMILES |
CC(C)(C)N1C(=O)C(=C(C=N1)OCC2=CC=C(C=C2)COCCF)Cl
|
|||
| InChI |
1S/C18H22ClFN2O3/c1-18(2,3)22-17(23)16(19)15(10-21-22)25-12-14-6-4-13(5-7-14)11-24-9-8-20/h4-7,10H,8-9,11-12H2,1-3H3/i20-1
|
|||
| InChIKey |
RMXZKEPDYBTFOS-LRFGSCOBSA-N
|
|||
| CAS Number |
CAS 863887-89-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mitochondrial complex I (NDUFA13) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01347710) A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.. U.S. National Institutes of Health. | |||
| REF 2 | The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med. 2011 Jul;41(4):305-13. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.